Literature DB >> 20561694

Dose volume parameter D2cc does not correlate with vaginal side effects in individual patients with cervical cancer treated within a defined treatment protocol with very high brachytherapy doses.

Elena F Fidarova1, Daniel Berger, Sandra Schüssler, Johannes Dimopoulos, Christian Kirisits, Petra Georg, Barbara Bachtiary, Richard Pötter.   

Abstract

The study aimed to determine whether post-radiation vaginal side effects in cervical cancer patients can be correlated with DVH parameter D(2cc). The result was negative in that no correlation could be demonstrated between D(2cc) and the presence and grade of side effects in this patients' subset treated with high brachytherapy doses.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2010        PMID： 20561694     DOI： 10.1016/j.radonc.2010.05.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  6 in total

1.  Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.

Authors:  Richard Pötter; Petra Georg; Johannes C A Dimopoulos; Magdalena Grimm; Daniel Berger; Nicole Nesvacil; Dietmar Georg; Maximilian P Schmid; Alexander Reinthaller; Alina Sturdza; Christian Kirisits
Journal:  Radiother Oncol       Date:  2011-08-05       Impact factor: 6.280

2.  Role of vaginal pallor reaction in predicting late vaginal stenosis after high-dose-rate brachytherapy in treatment-naive patients with cervical cancer.

Authors:  Ken Yoshida; Hideya Yamazaki; Satoaki Nakamura; Koji Masui; Tadayuki Kotsuma; Hironori Akiyama; Eiichi Tanaka; Nobuhiko Yoshikawa; Yasuo Uesugi; Taiju Shimbo; Yoshifumi Narumi; Yasuo Yoshioka
Journal:  J Gynecol Oncol       Date:  2015-04-29       Impact factor: 4.401

3.  Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies.

Authors:  Naoya Murakami; Takahiro Kasamatsu; Minako Sumi; Ryoichi Yoshimura; Ken Harada; Mayuka Kitaguchi; Shuhei Sekii; Kana Takahashi; Kotaro Yoshio; Koji Inaba; Madoka Morota; Yoshinori Ito; Jun Itami
Journal:  Radiat Oncol       Date:  2014-01-23       Impact factor: 3.481

Review 4.  Brachytherapy for malignancies of the vagina in the 3D era.

Authors:  Scott M Glaser; Sushil Beriwal
Journal:  J Contemp Brachytherapy       Date:  2015-09-14

5.  Computed Tomography-Guided Interstitial Brachytherapy for Locally Advanced Cervical Cancer: Introduction of the Technique and a Comparison of Dosimetry With Conventional Intracavitary Brachytherapy.

Authors:  Zhong-Shan Liu; Jie Guo; Yang-Zhi Zhao; Xia Lin; Bing-Ya Zhang; Chu Zhang; Hong-Yong Wang; Lei Yu; Xiao-Jun Ren; Tie-Jun Wang
Journal:  Int J Gynecol Cancer       Date:  2017-05       Impact factor: 3.437

6.  Patient's specific integration of OAR doses (D2 cc) from EBRT and 3D image-guided brachytherapy for cervical cancer.

Authors:  Edgar Gelover; Cabel Katherine; Christopher Mart; Wenqing Sun; Yusung Kim
Journal:  J Appl Clin Med Phys       Date:  2018-01-19       Impact factor: 2.102
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.